Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 
LETTER TO THE EDITOR
Ahead of print publication  

Expected usefulness of the third dose COVID-19 vaccine for cancerous patient


1 Private Academic Consultant Center, Bangkok, Thailand
2 Deparment of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India

Date of Submission23-Jun-2021
Date of Decision30-Jun-2021
Date of Acceptance03-Jul-2021
Date of Web Publication22-Jun-2022

Correspondence Address:
Rujittika Mungmunpuntipantip,
Private Academic Consultant Center, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.jcrt_1007_21



How to cite this URL:
Mungmunpuntipantip R, Wiwanitkit V. Expected usefulness of the third dose COVID-19 vaccine for cancerous patient. J Can Res Ther [Epub ahead of print] [cited 2022 Aug 18]. Available from: https://www.cancerjournal.net/preprintarticle.asp?id=347979



Sir,

COVID-19 vaccine is the hope for the management of worldwide COVID-19 outbreak. An important consideration for the new COVID-19 is on its efficacy. At present, most new COVID-19 requires the second dose boostering for promoting of effective immunity. In normal person, a two-dose vaccination can produce up to 100% protective antibody.[1] However, the postvaccination COVID-19 is sporadically reported and it leads to question on the present COVID-19 vaccination practice. There is a new idea for a three-dose vaccination for promoting a more effective immunity.[1]

A three-dose vaccination might be useful for some specific group with problem on postvaccination immunity production. For cancerous patient, a previous report shows that the second dose COVID-19 vaccine can increase immunity, but still less than normal person. Here, the authors estimate the utility of the third dose COVID-19 vaccine for cancerous patient. A clinical mathematical model study is used for calculating expected usefulness of the third dose COVID-19 vaccine for cancerous patient. Primary data from a previous referencing publication[2] are used for modeling. For case with solid cancer, the antisevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin-G (IgG) responses are equal to 38% (range: 26–51) and 95% (range: 75–99) after the first and second (at 33 weeks) COVID-19 dose, respectively.[2] For case with hematological cancer, the anti-SARS-CoV-2 IgG responses are equal to 18% (range: 10–32) and 60% (range: 23–88) after the first and second COVID-19 dose, respectively.[2]

The calculated increasing anti-SARS-CoV-2 IgG responses due to vaccine boostering are equal to 57%/3 weeks and 42%/3 weeks for solid cancer and hematological cancer groups, respectively. This value is used for the estimation of the effect of the additional third dose. If the third COVID-19 vaccine dose is given at the next week period after the second dose, the expected the anti-SARS-CoV-2 IgG responses will be equal to 100% and 100% (range: 65–100) for solid cancer and hematological cancer groups, respectively. From this modeling, it can show that the third dose of COVID-19 vaccine will be very useful for any cancerous patients.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 > References Top

1.
Iversen PL, Bavari S. Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2? Lancet Infect Dis 2021;21:1054-55.  Back to cited text no. 1
    
2.
Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study. Lancet Oncol 2021;22:765-78.  Back to cited text no. 2
    




 

 
Top
 
 
  Search
 
     Search Pubmed for
 
    -  Mungmunpuntipantip R
    -  Wiwanitkit V
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
>References

 Article Access Statistics
    Viewed133    
    PDF Downloaded0    

Recommend this journal